COMPARATIVE STUDY ON VACCINE-INDUCED AND NATURAL IMMUNITY TO COVID-19 IN HIGH-RISK POPULATIONS DHANBAD DISTRICT.

Main Article Content

Dr B.K. Pandey
Dr. Atul Prakash

Keywords

Prospective study, ELISA, Anti IgG Covid-19 antibody, Covaxine, Covalescent Plasma, RT-PCR

Abstract

Background:- The immune response following infection with a virus can be measured by detection of virus infected cells, IgM, IgG or total antibodies through immunoassay as well as by the detection of CD8+T cells. This prospective study investigates the comparative efficacy of vaccine-induced immunity and natural immunity in high-risk and susceptible groups in Dhanbad district. The study uses serological tests to measure immune response and assesses the benefits of 2 doses of Covaxine. The results provide insights into the need for booster doses and the overall immune response to COVID-19.


Methodology:-


This study has been conducted in SNMMCH hospital to establish any improved immunity in high risk and susceptible groups of professionals (paramilitary forces involved to implement government protocols, individuals involved in health care facilities to ascertain any added benefits of 2 doses of Covaxine over natural immunity developed due to accidental infection through contacts before pre-vaccination period. TruNat and RT-PCR was done for isolating exposed groups. Another group formed for those who are potential candidates for immunization with 2 doses of Covaxine with previous history of exposure of Covid-19 virus. All healthy people who will healthy in all clinical parameters were included in study according to sop.


Nasal swabs collected from all healthy individuals and CLIA method used to know the IgG cutt-off values.


Aims & Objectives:- This study aims to demonstrate any additional benefits for recipients of 2 doses of Covaxine,and to guide the potential need for precautionary or booster doses of the vaccine, especially for susceptible groups.

Abstract 37 | pdf Downloads 10

References

1. I.WorldHealthOrganization."lmmu11itypassports"inthecontextofCOV!D-19.Availa'room /commentaries/dctail/immunity-passports-in-the-context-of-covid-19
2. WorldHealthOrganization.Statementontbcseventhmeetingoftheln1crnationalHealCommineeregardingthecoronavirusdisease(COVID-19)pandemic.Availablefrom:l04-202l-s1alemem-on-1he-seventh-meeling-ol1he-intemutional-heal1h-regulations-{200the-coronavirus-disease-(covid-19)-pandemic
3. WajnbergA,MansourM,LevenE,etal.HumoralresponseandPCRpositivityinpatieCityregion,USA:anobservationalstudy.LancetMicrobe[lmemet]2020[cited2021h1rps:/llinkinghub. clsevier.eomfrctric\•cfpiifS266652472030 1208
4. GuthmillerJJ.Stovicck0,WangJ.ctal.SARS-CoV-2InfectionSeveritylsLinkedto:theSpike.mBio[lnrcmct)2021[cited2021Ytar26];12(1):c02940-20,/mbio/1211/mBi·https://mbio.asm.ondcoment/l2/I/e02940-20
5. WuJ.LiangB,ChenC,etal.SARS-CoV-2infectioninducessustainedhumoralimmwfollowingsymptomaticCOVID-19.NalCommun2021;12(1):1813.
6. HuangC,HuangL,WangY,etal.6-monthconsequencesofCOVID-19in patientsdis>study.TheLancet[Internet]2021[cited2021Apr22);397(10270):220-32.Availablef1htrps://Iinkinghub.elsevier.com/retrieve/pii/SO140673620326568
7. Arkhipova-.Jenkins1,HelfandM,AnnstrongC,et al.AntibodyResponseAfterSARS- 8. ScowJ,GrahamC,MerrickB,ctal.Longin1di11alobservationanddeclineofncutraliziJmonthsfollowingSARS-CoV-2infectioninl1umnns. NatMierobiol[Internet]2020[cilAvailablefrom:hllp://www.nalure.com/;irticles/41564-020-00813-8
9. LongQ-X.TangX-J,ShiQ-L,elal.Clinicalandimmunologicalasscssme111ofasympt•Med[l111emet]2020[cited2021Apr22):26(8):1200-4.Availablefrom:hllp://www.nat
10. WhealleyAK,JunoJA.WangJJ.elal.EvoluLionofimmune responsesloSARS-CoV-2iCommun[Internet]2021[cited2021Apr22];12(1):1162.Available from:hrtp://www.nal
11. DanJM,MateusJ,KaroY,etal.Immunologicalmemory toSARS-CoV-2assessedforScience[Internet]2021[cited 2021Mar26];371(6529):eabf4063.Availablefrom:https://www.scienccmag.org/lookup'doifl0.1.126/scicnccabf4063
12. SchwarzkopfS.CcUularImmunityinCOVID-19ConvalescentswithPCR-ConfinncdISARS-CoV-2-Spccific IgG.EmergInfectDis(Ln1erne1]Availablefrom:https://wwwm3772articlel/su!!!reSledcitation
13. SckineT,Perez-PottiA.Rivern-Ballesteros0.etal.RobustTCellImmunityinConvalAsymptomaticorMildCOVID-19.Cell2020:183(1):158-168.el4.
14. WheatleyAK,JunoJA.WangJJ,elal.Evolutionofimmunity10SARS-CoV-2[lntemtHIV/AIDS);2020[cited2021Mar26).Availablefrom:hnp://medrxiv.org/lookup/doi/
15. PolandGA,OvsyannikovaJG,KennedyRB.SARS-CoV-2immunity:reviewandapplicandidates.TheLancer[Internet]2020[cited2021AprI6];396(10262):1595-606.Avahtrps://linkinghub.elsevier.com/rerrieve/pii/SO140673620321371
16. EdridgeAWD,KaczorowskaJ,HosteACR.elal. Seasonalcoronavirusprotectiveimm
Qnternet]2020 [cited2021Mar26];26(11):1691-3.Availablefrom:hup://www.narure
17. HuangAT,Garcia-CarrerasB,Hitchings MDT,etal.Asystematicreviewofantibody1kinetics,correlatesofprotection,aadassociationwithseverity.NatCommun(lotcmet]
15);11(I):4704.Availablefrom:http://www.natprc.com/articlcs/s41467-020-18450-4
18. GuoX,GuoZ,DuanC,ctal.Long-TermPersistenceoflgGAntibodies inSARS-CoVflntcrnct]. InfectiousDiseases(exceptlilV/AIDS);2020[cited 2021Apr15].Ava.ilablchttp://medrxiv.org/lookup/doi/I0.1101/2020.02.12.20021386
19. WuL-P,Wang-C,ChangY-H,etal.DurationofAntibodyResponsesafterSevereAInfectDis[lnterner]2007[cited2021Apr15];13(10):1562-4.Availablefrom:hrm://w, 0576 article.hon
20. AndersonDE,TanCW,ChiaWN,ctalLackofcross-ncutralizarion bySARSpaticnr! Microbeslnfecr2020;9(1):900-2.
21. AlshukairiAN, ZhaoJ,AJ-MozainiMA.WangY,DadaA,BaharoonSA,ctal.Longc1syndromecoronavirusantibodyresponsesinhumans.SaudiAmbia.EmergInfectDis.'.
22. HarveyRA,RassenJA.KabelacCA.etal.AssociationofSARS-CoV-2SeropositiveAlnf'ection.JAMAIntern ed[lntemet]2021[cired2021Mar26);
Availablefrom:htrps://jamanerwork.com/joumals/jamaintemalmedicine/fullanicle/2776810
23. LumleySF,0'DonnellD,Stoesser lE.etal.AntibodyStatusandIncidenceofSARS-1Workers.NEngl JMed[Internet]2021[cited 2021Mar26];384(6):533-40. Availablehnp://www.nejm.org/doi/ I0.I056/NEJMoa2034545
24. HansenCH,MichlmayrD,GubbelsSM,MolbakK,F.thelbergS.Assessmentofprotec1CoV-2among4 millionPCR-testedindividualsinDenmarkin2020: apopulation-levelllntemet] 2021[cited202I Mar27];397(10280):!204-12.Availablefrom: htlps://linkinf!hub. elsevier.com/ retricve/pii/SO140673621005754
25. I!allVJ,FoulkesS,Charletl A,etal.SARS-CoV-2 infectionrntcsofantibody-positive health-careworkersinEngland:alarge,multicentre,prospectivecohortstudy (SIREN).202IApr15];SO14067362I006759.Availablefrom:hups;//1inkinghub.elsevier.com/rel
26. Wang P,NairMS,Liu L,etal.AntibodyResistanceofSARS-CoV-2VariantsB.1.351 [cited2021 Mar30] z;Availablefrom:http://www.naturc.com/nniclcs/s41.)86-021-0339
27. PlanasD,BnielT,GrzelakL,etal.SensitiviryofinfectiousSARS-CoV-2B.1.1.7andB.I.NatMed(lntcmet]2021[cited2021Mar30];Availablefrom:http://www.narurc.com/articlc
28. WangP,WangM,YuJ,ctal.IncreasedResistanceofSARS-CoV-2VariantP.1toAnt Microbiology:2021[cited2021Mar30j.Availablefrom: hup://biorxiv.orn/lookup/doii



29. ZhouD,DejnirattisaiW.SupasaP.etal.EvidenceofescapeofSARS-CoV-2variantBinducedsera.Cell[Internet]2021[cited2021Mar 30];S0092867421002269.Availablehtrns:/11inkinehub.elsevier.com/retrievefpii/S0092867-12I002269
30. AbdoolKarimSS,deOliveiraT.NewSARS-CoV-2Variants Clinical,PublicHealdJMed [Internet] 2021[cited2021Mar26];NEJMc2100362.Availablefrom:http://www.nejm.on!/doi/10.1056/NEJMc2I00362
31. WorldHealthOrganization.DiagnostictestingforSARS-CoV-2.Availablefrom: https://www.who.int/publications/i/item/dia!lnO>Iic-tcsting-for-sars-cov-2
32. WorldHealthOrganization.Adviceoat11cuseofpoint-of-careinununodiagnostictestsfohttps://www.who.intlnews-roorn/commcnrarics/dctail/advicc-on-the-usc-of-point-of-carc-
33. KrammerF. CorrelarcsofprorcctionfromSARS-CoV-2infection.TheLancet[Internet